• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [19081 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     NIHR Health Technology Assessment programme Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis (The EASI-SWITCH Trial)
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of opicapone (Ongentys®) for the treatment of Parkinson's disease
2021     NIHR Public Health Research (PHR) programme Safetxt:A randomised controlled trial of an intervention delivered by mobile phone messaging to reduce sexually transmitted infections (STI) by increasing sexual health precaution behaviours in young people.
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Equine immunoglobulin F(ab’)2 fragments (hyperimmune equine serum) for COVID-19]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of givosiran (Givlaari®) for the treatment of acute hepatic porphyria
2021     NIHR Health Technology Assessment programme HTA-SYMBAD StudY of Mirtazapine or carBamazepine for Agitation in Dementia
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ivermectin for COVID-19]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment oxybutynin intravesical solution (Vesolox®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cenobamate (epilepsy) - Addendum to Commission A21-78]
2021     NIHR Health Technology Assessment programme Sacral nerve stimulation versus the magnetic sphincter augmentation device for adult faecal incontinence: the SaFaRI RCT
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2021     Agency for Care Effectiveness (ACE) MRI-US fusion targeted biopsy for diagnosis of prostate cancer
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice mexiletine (Namuscla®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Addendum to Commission A21-77]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketogenic diet in central nervous system tumors]
2021     Agency for Care Effectiveness (ACE) Transcatheter mitral valve leaflet repair for patients with mitral regurgitation
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V. Addendum]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Teduglutide in short bowel syndrome]
2021     Agency for Care Effectiveness (ACE) Transcatheter aortic valve implantation (TAVI) for patients with symptomatic severe aortic stenosis
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [High frequency ablation of the endometrium using a mesh electrode in patients with menorrhagia]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl-peptidase 4 inhibitors in patients with prediabetes or metabolic syndrome]
2021     Agency for Care Effectiveness (ACE) Photodynamic therapy for treating non-melanoma skin tumours
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Tolvaptan in autosomal dominant polycystic kidney disease]
2021     Agency for Care Effectiveness (ACE) Cochlear implants for treating adults with single-sided deafness (SSD)
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Tocilizumab in COVID-19 patients]
2021     Agency for Care Effectiveness (ACE) Antibacterial envelope for the prevention of cardiac implantable electronic device-related infections
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Allocation of scarce resources in critical care units in a pandemic]
2021     Agency for Care Effectiveness (ACE) Repetitive transcranial magnetic stimulation for adults with treatment resistant major depressive disorder
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Second addendum to commission A21-84]
2021     NIHR Health Technology Assessment programme Cognitive–behavioural therapy for a variety of conditions: an overview of systematic reviews and panoramic meta-analysis
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [SGLT2 inhibitors in heart failure]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (malignant pleural mesothelioma) - Addendum to Commission A21-89]
2021     NIHR Health Technology Assessment programme Patch augmentation surgery for rotator cuff repair: the PARCS mixed-methods feasibility study
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ambulatory oxygen therapy in COVID-19]
2021     NIHR Health Services and Delivery Research programme Respite care and short breaks for young adults aged 18–40 with complex health-care needs: mixed-methods systematic review and conceptual framework development
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2021     Norwegian Institute of Public Health (NIPH) Surgery for carpal tunnel syndrome: a health technology assessment
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Eye controlled speech generating device]
2021     NIHR Health Technology Assessment programme Universal late pregnancy ultrasound screening to predict adverse outcomes in nulliparous women: a systematic review and cost-effectiveness analysis
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Risdiplam in spinal muscular atrophy]
2021     Agency for Care Effectiveness (ACE) Golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis
2021     Norwegian Institute of Public Health (NIPH) Evaluation of tests for FLT3 mutations in acute myeloid leukaemia (AML)
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Stem cell therapy: clinical applications]
2021     NIHR Health Technology Assessment programme DISC: Dupuytren's Interventions Surgery vs. Collagenase. A pragmatic multi-centre randomised controlled non-inferiority, cost effectiveness trial comparing injections of collagenase into the cord to surgical correction in the treatment of moderate Dupuytren's contracture in adult patients
2021     Norwegian Institute of Public Health (NIPH) Subacromial decompression surgery for impingement syndrome: rapid health technology assessment
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Non-invasive respiratory support in Covid-19 patients]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Brolucizumab in neovascular age-related macular degeneration]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [COVID-19: follow-up after an acute episode]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Microperimetry in retinopathies]
2021     NIHR Health Technology Assessment programme Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTILA RCT
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Cardiopulmonary resuscitation in COVID-19 patients]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for updating the DMP "Heart failure"]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical Practice Guideline on adult's palliative care]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Patisiran and inotersen in hereditary transthyretin-mediated amyloidosis]
2021     NIHR Health Technology Assessment programme Impact of multiparametric MRI on staging and management of patients with suspected or confirmed ovarian cancer Short title: MR in Ovarian Cancer (MROC study)
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Whole-exome sequencing in patients with neurological disorders]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Angiotensin II acetate (refractory hypotension in distributive shock) - Addendum to Commission A21-95]
2021     NIHR Health Services and Delivery Research programme Pay More Attention: a national mixed methods study to identify the barriers and facilitators to ensuring equal access to high quality hospital care and services for children and young people with learning disability and their families
2021     NIHR Health Technology Assessment programme UK Cohort study to Investigate the prevention of Parastomal Hernia (CIPHER)
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Transcatheter aortic valve implantation in severe aortic stenosis]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating pharmacological treatment for clearing an occluded central venous access device (CVAD)]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Swallowable gastric balloon in obesity]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Whole exome sequencing in patients with intellectual disability and/or autism spectrum disorder]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Extracranial stereotactic body radiotherapy in oligometastasis]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafasitamab (diffuse large cell B-cell lymphoma, combination with lenalidomide) - Assessment according to § 35a (1), Sentence 11, Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Whole exome sequencing in epileptic encephalopathies]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Odevixibat (cholestasis [from 6 months]) - Assessment according to § 35a (1), Sentence 11, Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Baricitinib in COVID-19 patients]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Edaravone in patients with amyotrophic lateral sclerosis]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (basal cell carcinoma) - Addendum to Commission A21-97]
2021     Norwegian Institute of Public Health (NIPH) [Intravenous immunoglobulin treatment in children with PANS/PANDAS conditions]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Hemlibra(emicizumab) – Hemophilia A without inhibitor (re evaluation)]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Benefit assessment according to §35a Social Code Book V]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Lyme disease and persistent symptoms: a look at the current knowledge and recommendations for improving management]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec - Second addendum to Commission A20-61]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: clinical utility of the different Western blot antigen profiles in the context of disseminated Lyme disease]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis, homozygous F508del mutation in the CFTR gene, 2-5 years) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: chronic” Lyme disease: current state of knowledge and overview of the different perspectives]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence on orphan drugs]
2021     NIHR Health Technology Assessment programme Prognostic tools for identification of high risk in people with Crohn’s disease: systematic review and cost-effectiveness study
2021     Scottish Medicines Consortium (SMC) Afamelanotide (Scenesse) for prevention of photoxicity in adult patients with erythropoietic protoporphyria (EPP)
2021     NIHR Health Technology Assessment programme A multicentre randomised controlled trial of induced endometrial trauma in women undergoing first time In Vitro Fertilisation (IVF)
2021     Scottish Medicines Consortium (SMC) Upadacitinib for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)
2021     NIHR Health Technology Assessment programme Risks and benefits of bisphosphonate use in patients with chronic kidney disease: a population-based cohort study
2021     Scottish Medicines Consortium (SMC) Ravulizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity; in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months
2021     NIHR Health Technology Assessment programme Facilitating the return to work of NHS staff with common mental health disorders: a feasibility study
2021     Scottish Medicines Consortium (SMC) Ozanimod for adult patients with relapsing remitting multiple sclerosis
2021     NIHR Health Technology Assessment programme QUIDS Quantitative fibronectin to help decision-making in women with symptoms of preterm labour
2021     NIHR Health Technology Assessment programme The Invasive Dentistry Endocarditis Association Study: the IDEA Study
2021     Scottish Medicines Consortium (SMC) Entrectinib as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion: who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity; and who have not received a prior NTRK inhibitor; who have no satisfactory treatment options
2021     NIHR Health Technology Assessment programme Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT
2021     NIHR Health Technology Assessment programme Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT
2021     Scottish Medicines Consortium (SMC) Onasemnogene abeparvovec treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: validation of the management framework for a nonspecific human immunoglobulin shortage]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: standards for the management of acute ST-segment elevation myocardial infarction (STEMI) in Québec (update of April 2021)]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Internet-based psychological treatment for anxiety and depression (an update)
2021     Scottish Health Technologies Group (SHTG) NHSScotland COPD Support Service: remote and self-management of high-risk patients with COPD using a web app and machine learning predictive modelling
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Occupational exposure and upper extremity pain
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Diagnostics and treatment of provoked vestibulodynia